<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289236</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102252</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-163-21880-13013339</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130121</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-163-21880-13013339</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reportergivename>Darrell</reportergivename>
      <reporterfamilyname>Willyard</reporterfamilyname>
      <reporterstreet>Tulsa Cancer Institute, 1810 E 15th Street</reporterstreet>
      <reportercity>Tulsa</reportercity>
      <reporterstate>OK</reporterstate>
      <reporterpostcode>74104</reporterpostcode>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>R-A</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19400419</patientbirthdate>
      <patientsex>1</patientsex>
      <patientmedicalhistorytext lang="en">None Provided</patientmedicalhistorytext>
      <patientdeath>
        <patientdeathdateformat>102</patientdeathdateformat>
        <patientdeathdate>20130116</patientdeathdate>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">PASSED AWAY</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20130116</reactionstartdate>
        <reactionfirsttime>4</reactionfirsttime>
        <reactionfirsttimeunit>802</reactionfirsttimeunit>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">25 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201209</drugstartdate>
        <drugstartperiod>4</drugstartperiod>
        <drugstartperiodunit>802</drugstartperiodunit>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">PASSED AWAY

(USA) Initial information received on 21/Jan/2013.  A pharmacist called to report the death due to an unknown cause of a 72 year old  male patient who received Revlimid 25 mg capsules orally daily.  The lot number was A0176C and the expiration date was 31Jan2015. The date of death was 16Jan2013.  The report stated that the patient expired after hospitalization. The dates and indication for the hospitalization were not reported.  Based on prior information previously provided by the prescriber this patient received therapy with Revlimid from /Sep/2012 to an unknown date  for the treatment of multiple myeloma.  The reporter did not provide a causality assessment for the death and therapy with Revlimid.  
 Additional information will be requested from the prescriber.</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and PASSED AWAY suggest that a causal relationship is possible, but underlying disease could provide an alternative explanation.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
